Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4F2 | P78329 | 2/20 | 0.56 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | HRH1 | P35367 | 1/20 | 0.50 |
| ▸ | TBXAS1 | P24557 | 3/20 | 0.48 |
| ▸ | TLR2 | O60603 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.44 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.44 |
| ▸ | CYSLTR2 | Q9NS75 | 1/20 | 0.44 |
| ▸ | CYSLTR1 | Q9Y271 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2964336 | 0.99 | CYP4F2 (0.57) | CYP4F2CYP4A11LMNACYP1A2CYP2C19 | |
| SCHEMBL1859504 | 0.94 | CYP1A2 (0.57) | CYP4F2CYP4A11LMNACYP1A2CYP2C19 | |
| SCHEMBL4341122 | 0.88 | LMNA (0.57) | CYP4F2CYP4A11LMNACYP1A2CYP2C19 | |
| SCHEMBL6643882 | 0.85 | SMN1; SMN2 (0.55) | LMNACYP1A2CYP2C19SMN1; SMN2HRH1 | |
| SCHEMBL11174442 | 0.84 | CYSLTR2 (0.49) | CYP4F2CYP4A11LMNATBXAS1ALDH1A1 | |
| SCHEMBL2959192 | 0.84 | SMN1; SMN2 (0.47) | CYP4F2CYP4A11CYP1A2CYP2C19SMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL10659395 | 0.82 | DGKA (0.55) | LMNACYP1A2CYP2C19SMN1; SMN2TLR2 | |
| SCHEMBL2955452 | 0.82 | SMN1; SMN2 (0.48) | CYP4F2CYP4A11CYP1A2CYP2C19SMN1; SMN2 | |
| Ethyl Acetate SCHEMBL8398014 | 0.82 | HRH1 (0.49) | LMNACYP1A2CYP2C19SMN1; SMN2HRH1 | |
| SCHEMBL6245103 | 0.80 | CYP1A2 (0.58) | LMNACYP1A2CYP2C19SMN1; SMN2HRH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7250510-B2 | Transition metal complexes of N-heterocyclic carbenes, method of preparation and use in transition metal catalyzed organic transformations | TOTAL SYNTHESIS, LTD. (CA) | 2007-07-31 | — | — | US | disclosed |
| US-7250510-B2 | Transition metal complexes of N-heterocyclic carbenes, method of preparation and use in transition metal catalyzed organic transformations | TOTAL SYNTHESIS, LTD. (CA) | 2007-07-31 | — | — | US | disclosed |
| US-20070073055-A1 | Transition metal complexes of N-heterocyclic carbenes, method of preparation and use in transition metal catalyzed organic transformations | TOTAL SYNTHESIS, LTD. (CA) | 2007-03-29 | — | — | US | disclosed |
| US-20070073055-A1 | Transition metal complexes of N-heterocyclic carbenes, method of preparation and use in transition metal catalyzed organic transformations | TOTAL SYNTHESIS, LTD. (CA) | 2007-03-29 | — | — | US | disclosed |
| CN-1224624-C | 1, 8-naphthyridin-2 (1H) -one derivatives | GRELAN PHARMACEUTICAL CO (JP) | 2005-10-26 | — | — | CN | disclosed |
| EP-1236725-B1 | NOVEL 1,8-NAPHTHYRIDIN-2(1H)-ONE DERIVATIVES | GRELAN PHARMACEUTICAL CO (JP) | 2004-03-10 | — | — | EP | disclosed |
| US-6642250-B2 | As phosphodiesterase inhibitor for prophylaxis and therapy of bronchial asthma; pneumonic diseases, pulmonary emphysema, chronic obstructive pulmonary disease acute respiratory distress syndrome (ARDS), and other respiratory diseases | GRELAN PHARMACEUTICAL CO., LTD. (JP) | 2003-11-04 | — | — | US | disclosed |
| CN-1407984-A | Novel 1, 8-naphthyridin-2 (1H) -one derivatives | GRELAN PHARMACEUTICAL CO (JP) | 2003-04-02 | — | — | CN | disclosed |
| US-20030036651-A1 | Novel 1,8-naphthyridin-2(1h)-one derivatives | GRELAN PHARMACEUTICAL CO., LTD. (JP) | 2003-02-20 | — | — | US | disclosed |
| EP-1236725-A1 | NOVEL 1,8-NAPHTHYRIDIN-2(1H)-ONE DERIVATIVES | Grelan Pharmaceutical Co., Ltd. (JP) | 2002-09-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030036651-A1 | Novel 1,8-naphthyridin-2(1h)-one derivatives | PDE3B, PDE4A, PDE4B | CYP4F2 705/4885CYP4A11 32/4885LMNA 2801/4885 |
| US-20070073055-A1 | Transition metal complexes of N-heterocyclic carbenes, method of preparation and use in transition metal catalyzed organic transformations | NDC1, NBAS, NUDC | CYP4F2 218/4885CYP4A11 570/4885LMNA 1075/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.